Latest Breaking News On - Otsuka pharmaceutical europe - Page 1 : comparemela.com

Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap.

Abilify maintenaPeter gillbergOtsuka europeJohan luthmanEuropean commissionOtsuka pharmaceutical company ltdOtsuka holdings co ltdHead of medical affairs at otsuka europeEuropean unionOtsuka pharmaceutical europe ltdHead of research development at lundbeckOtsuka pharmaceutical europeExecutive vice presidentVice presidentMedical affairsPharmaceutical europe

Astex Pharmaceuticals, Inc : Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

Astex Pharmaceuticals, Inc : Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAlison rossOtsuka europeMartin bucklandOtsuka holdings co ltdAstex pharmaceuticals incTaiho oncology incOtsuka pharmaceutical company ltdEuropean medicines agencyEuropean hematology association congressOtsuka pharmaceutical co ltdEuropean commissionOtsuka pharmaceutical europe ltdAmerican society of hematology annual meetingTaiho pharmaceutical co ltdOtsuka pharmaceutical europe

Otsuka s Lupkynis granted EC approval as active lupus nephritis treatment

Otsuka s Lupkynis granted EC approval as active lupus nephritis treatment
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United kingdomNorthern irelandBrandy hodgeEurope otsukaEuropean commissionDrug administrationRegulatory agencyOtsuka pharmaceutical europeUnited kingdom medicines

Otsuka announces EC approval of Lupkynis®▼ (voclosporin) as first oral treatment for active lupus nephritis

Otsuka Pharmaceutical Europe Ltd. today announces that the European Commission (EC) has approved Lupkynis® (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). The EC decision applies .

United kingdomNorthern irelandCity ofOtsuka europeBrandy hodgeOtsuka pharmaceutical europe ltdEuropean unionEuropean commissionOtsuka pharmaceutical company ltdOtsuka holdings co ltdOtsuka pharmaceutical europePharmaceutical europeOtsuka pharmaceutical company

Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
bctechnology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bctechnology.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPeter greenleafSue evansEuropean congressAurinia pharmaceuticals incEuropean commissionDrug administrationEuropean alliance of associationsOtsuka pharmaceutical europe ltdEuropean unionEuropean medicines agencyOtsuka pharmaceutical development commercialization incOtsuka pharmaceutical co ltdEuropean renal associationAurinia pharmaceuticals